[Correspondence] Dysphagia-optimised intensity-modulated radiotherapy versus standard radiotherapy in patients with pharyngeal cancer – Authors’ reply

We thank the readers for their kind comments on our work. Ahitagni Biswas and colleagues rightly point out that over 80% of patients in the DARS trial had human papilloma-virus (HPV) positive oropharyngeal cancer.1 In India, less than a quarter of patients present with this type of cancer and most patients have more locally advanced disease. They therefore question whether the results of DARS can be reproduced in community practice in India.